Should Doctors Be Allowed to Recommend Cannabis? An Australian Perspective | Research

The takeaway

An Australian working party recommended granting legal exemptions for patients with specific medical conditions to use cannabis, even though cannabinoid drugs were not formally registered.

Read this if you want to understand how the medical cannabis policy conversation developed in Australia before formal legalization.

NSW Working Party recommended legal exemption for certified patients

What the researchers found

Cannabis had been advocated as a treatment for nausea, vomiting, wasting, pain, and muscle spasms across cancer, HIV/AIDS, and neurological conditions. However, cannabinoid drugs were not registered for medical use in Australia, and the authors noted that a smoked plant product was unlikely to meet registration standards.

A New South Wales Working Party recommended a middle path: granting exemption from prosecution for patients who were medically certified to have specified conditions. The authors argued this approach deserved consideration by other Australian state and territory governments.

Why it matters

This piece captured a moment when Australia was grappling with the gap between patient demand for cannabis as medicine and the regulatory frameworks that prohibited it. The recommendation for prosecution exemptions rather than full legalization represented a cautious, incremental approach that many countries would later adopt in various forms.

The numbers in context

No quantitative data were presented in this editorial.

How the study worked

This was a short editorial commentary reviewing the state of cannabis policy in Australia and the recommendations of a New South Wales government working party. It did not involve original data collection or systematic review methodology.

What this study cannot tell us

This was an opinion piece, not a systematic analysis of evidence. It represented the views of three authors and did not provide comprehensive data on efficacy or safety. The short format (two pages) limited the depth of policy analysis.

How to read the evidence

This is an editorial commentary without original data or systematic methodology, placing it at the preliminary evidence level.

When this study was published

Published in 2001, this predates Australia's 2016 medical cannabis scheme by 15 years.

The bigger picture

Australia would eventually establish a medical cannabis access scheme in 2016 through the Therapeutic Goods Administration. This 2001 editorial shows that the policy conversation was already underway years before formal legislation, driven by patient advocacy and emerging clinical evidence from other countries.

Questions still open

How did prosecution-exemption models compare with prescription-based models in terms of patient access and safety oversight? Did incremental policy changes like this accelerate or delay the development of formal medical cannabis programs?

Common questions

Did Australia eventually legalize medical cannabis?

Yes. In 2016, Australia passed federal legislation allowing access to medical cannabis through the Therapeutic Goods Administration, more than a decade after this editorial was published.

Why was smoked cannabis unlikely to be registered as medicine?

The authors noted that regulatory bodies generally require standardized pharmaceutical products, and a smoked plant product does not meet typical drug registration standards for dosing consistency, safety, and delivery method.

Read the original research

Allowing the medical use of cannabis.

The Medical journal of Australia, 175(1), 39-40

View on PubMed ↗

Citation

Hall, W D; Degenhardt, L J; Currow, D. (2001). Allowing the medical use of cannabis.. The Medical journal of Australia, 175(1), 39-40.